Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Aflibercept is the active ingredient of these drugs:
Australia Austria Canada Cyprus France
Austria Brazil Cyprus France Hong Kong
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):